Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review by Fornaro, Michele et al.
Neuropsychiatric Disease and Treatment Dovepress
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
© 2016 Fornaro et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2016:12 719–735submit your manuscript | www.dovepress.com
Dovepress 
719
http://dx.doi.org/10.2147/NDT.S100846
Prevalence and clinical features associated with 
bipolar disorder polypharmacy: a systematic review
Michele Fornaro1
Domenico De Berardis2
Ann Sarah Koshy3
Giampaolo Perna4
Alessandro valchera5
Davy vancampfort6
Brendon Stubbs7,8
1New York Psychiatric institute, 
Columbia University, New York, 
NY, USA; 2National Health Service, 
Department of Mental Health, 
Psychiatric Service of Diagnosis and 
Treatment, Hospital “G. Mazzini”, 
Teramo, italy; 3St. John’s National 
Academy of Health Sciences, 
Bangalore, india; 4Department of 
Clinical Neurosciences, Hermanas 
Hospitalarias - villa San Benedetto 
Menni Hospital, FoRiPsi, 5Hermanas 
Hospitalarias, FoRiPsi villa S. 
Giuseppe Hospital, Ascoli Piceno, 
italy; 6Department of Rehabilitation 
Sciences, KU Leuven, Leuven, 
Belgium; 7Physiotherapy Department, 
South London and Maudsley NHS 
Foundation Trust, 8Health Service and 
Population Research Department, 
institute of Psychiatry, King’s College 
London, London, UK
Background: Uncertainty exists regarding the prevalence and clinical features associated 
with the practice of polypharmacy in bipolar disorder (BD), warranting a systematic review 
on the matter.
Methods: Three authors independently searched major electronic databases from inception till 
September 2015. Articles were included that reported either qualitative or quantitative data about 
the prevalence and clinical features associated with polypharmacy in adult cases of BD.
Results: The operative definitions of polypharmacy adopted across varying studies varied, with 
concomitant use of two or more psychotropic medications or use of four or more psychotropic 
medications at once being the most common and the most reliable, respectively. Regardless of 
type or current mood episode polarity of BD, prevalence rates up to 85% and 36% were found 
using the most permissive (two or more medications at once) and the most conservative (four or 
more) operative definitions for polypharmacy, respectively. Point prevalence prescription rates of 
one or more antidepressant or antipsychotic as part of a polypharmacy regimen occurred in up to 
45% or 80% of the cases, respectively, according to the most permissive definition of polyphar-
macy. In contrast, lithium prescription rates ranged from 13% to 33% in BD patients receiving 
polypharmacy according to conservative and permissive definitions, possibly suggesting a reduced 
need for augmentation of combination strategies for those cases of BD with a favorable lifetime 
lithium response and/or long-lasting treatment as well as less likelihood of lithium response over 
the time most severe cases possibly exposed to a more complex polypharmacy overall.
Limitations: “Apples and oranges” bias; publication bias for most recently introduced 
compounds.
Conclusion: Polypharmacy is common among people with BD across varying type and mood 
episode phases of illness. Special population, including BD patients at high risk of familial load 
for suicidal behavior, solicit further research as well as the plausible “protective” role of lithium 
toward polypharmacy in BD. The PROSPERO registration number is CRD42014015084.
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Introduction
Bipolar patients include an eclectic mix of ages and diagnostic categories across 
varying states of health, often receiving complex and long-lasting pharmacological 
interventions. In a community study, up to 9% of psychiatric patients received 
polypharmacy.1 These rates increase to 13% in general population and an alluring 
90% in general psychiatric settings.2 Polypharmacy point prevalence rates up to 40% 
(according to the definition of three or more medications at once) or 18% (in case of 
four or more concomitant medications) have been reported for bipolar disorder (BD) 
cases suffering from long-lasting and/or treatment-resistant depression and receiving 
antidepressant drugs.3 Furthermore, most of the available information about psychiatric 
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medications comes from drug development programs that 
lead to registration and marketing. These programs almost 
invariably study the new drug in isolation vs either placebo 
or a comparator agent.4 Experience with any new psychi-
atric medication in combination with another intervention 
is therefore virtually limited to a few short-term drug–drug 
interaction studies that are usually conducted in carefully 
screened young healthy volunteers.5 Nevertheless, the prac-
tice of polypharmacy in BD represents the rule rather than 
the exception in the clinical setting, regardless of the current 
polarity of mood episode.3,6–8 A number of reasons endorse 
the clinical practice of polypharmacy, with failure to achieve 
remission being the most common one.9 This reflects the find-
ings from the most comprehensive “real-world” pharmaco-
logical trial on BD patients to date, the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD),10 
in which up to 42% of the symptomatic patients included at 
baseline did not achieve recovery within 2 years of follow-up, 
despite expert pharmacotherapy and psychotherapy.11 Aimed 
at shedding light on the matter, a set of 12 useful criteria has 
been proposed for a rational polypharmacy, essentially focus-
ing on pharmacokinetic and pharmacodynamics issues,5 as 
previously done by other authors comparing different phases 
of BD.12 Yet, it has not been investigated which bipolar 
patients were most exposed to polypharmacy. There is clini-
cally sound predictive value for a past history of treatment. 
This is seen in cases that include resistant bipolar depres-
sion, sub- or full-threshold mixed features, rapid-cycling 
course, or affective temperaments (especially cyclothymic 
one). They represent a few potential clinical moderators of 
“hard-to-catch” issues for standard treatment of guidelines 
for BD.13,14 Standard treatment guidelines on BD pose little 
or no attention overall toward the matter of polypharmacy, 
especially in relationship to the past history of treatment, 
which includes resistant bipolar depression, sub- or full-
threshold-mixed features, rapid-cycling course, or affective 
temperaments (especially cyclothymic one), despite their 
clinically sound predictive value overall.13,14 Both evidence 
in support of4,15,16 and in dispute against17–19 the practice of 
polypharmacy have been advocated to date. However, data 
about the actual prevalence and clinical correlates of the 
practice beyond the essential pharmacological and neuro-
biological premises are limited.
Therefore, we conducted a systematic review to assess 
the prevalence rates and clinical correlates across varying 
definitions of polypharmacy and varying mood phases of 
adulthood BD.
Materials and methods
This systematic review adhered to the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) 
(http://www.prisma-statement.org/)20 following a regis-
tered publically available protocol (PROSPERO number: 
CRD42014015084).
eligibility criteria
We limited our search to those records including adult 
subjects with BD, published in peer-reviewed journals. 
Limits activated were species: humans, language: English, 
and all adult: 19+, with no publication date restriction.
information sources and search strategy
Sources of information included the following databases 
last accessed on September 11, 2015: PubMed/MEDLINE, 
Scopus, PsycINFO, EMBASE, Cochrane library, and Google 
Scholar. Contact with study authors was planned in advance 
whenever needed. The following keywords or their combina-
tion were used in the search strategy: “Bipolar Disorder” AND 
“polypharmacy” either in the title or in the abstract (or in the 
keywords, if allowed to be specified). Therefore, the adopted 
PubMed string was “Bipolar Disorder AND polypharmacy” 
(any field). Finally, the terms “polypharmacy,” “poly-
pharmacotherapy,” “polypharmacology,” “polytherapy,” and 
“copharmacy” were used interchangeably across multiple 
databases.
Study selection
Included papers were those reporting epidemiological data 
about the prevalence and clinical features associated with 
polypharmacy in course of BD, with no restriction on etiology, 
bipolar type, specifiers/features, phase of illness or pharmaco-
logical and/or nonpharmacological treatment, class, dose, or 
duration of the pharmacological trials. Papers covering cases 
of polypharmacy in BD comorbid with additional disorders 
(either psychiatric or medical disorders/diseases) were also 
accounted whenever available. When a title and/or an abstract 
appeared suggestive for inclusion, the full-text reprint was 
obtained and examined to assess its relevance according to 
our inclusion/exclusion criteria. Excluded papers were case 
reports, oral communications, papers not including BD cases 
(multidiagnostic samples were nonetheless allowed) receiving 
multiple psychopharmacological treatments at once (any indi-
cation), those merely focusing on neurobiological, genetic, or 
pharmacological aspects of either BD or polypharmacy, those 
including (only) children or adolescents, or without an accurate 
description of the operative constructs of polypharmacy.
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Data collection process
Three authors (MF, BS, and DV) conducted a two-step 
literature search, examining all titles and abstracts, access-
ing the full texts of potentially relevant papers. On data 
collection and extraction, the appointed authors compared 
their own results with each other to reach a final consensus 
based on consensual inclusion and exclusion criteria. Any 
possible discrepancy between the principal investigators, 
blind to each other, was solved by consultation with three 
reviewing authors (ASK, DDB, and GP). Both autosearch 
and hand search for “type I” (duplicates among/across 
different databases) and “type II” (duplicate publications in 
different Journals/issues)21 were performed using Thomson 
Reuters EndNote X7™ for Microsoft Windows™. Data 
were screened for the following characteristics: Participants, 
Interventions, Comparisons, Outcomes, and Study Design 
(PICOS) as well as funding sources. Specifically, the 
recorded variables for each article included in the review 
were author(s), year publication, study design, sample size, 
eventual follow-up or control group, sociodemographic 
status, concurrent psychotherapy or history of physical treat-
ment for BD, outcome measures, conclusions, limitations, 
quality score, and quality differentiation.
Risk of bias in individual studies
Potential major confounding biases in the studies have 
been ascertained at study level focusing on the follow-
ing: measurement/diagnostic bias (especially inconsistent/
unreliable definitions of polypharmacy and/or lack of reliable 
diagnostic tools to make the diagnosis of BD), confound-
ing bias (eg, lack of stratification and multivariate control 
for specific sociodemographic, vital, or clinical features), 
information (especially recall) bias, unrepresentativeness or 
inhomogeneity of the sample size or lack of control group, 
and selection by indication bias (nonrandom assignment of 
the exposure where applicable).22
Summary measures
Summary measures were risk ratio for cohort studies, odds 
ratio (OR) for case–control studies, or difference in mean 
values. Cohen’s d effect sizes were reported, whenever avail-
able or anyway ascertainable.
Scoring and ranking of the studies
The assessed studies were rated for quality using the fol-
lowing eligibility criteria: 1) representativeness of the 
sample (0–1 point); 2) presence of BD patients only in the 
sample (0–2 points); 3) a priori study design with the goal 
of evaluating the epidemiology of polypharmacy in BD 
(0–2 points); 4) extension of the follow-up (longitudinal 
studies)/clinical records (retrospective studies) .1 year 
(0–2 points); 5) validation of the clinical diagnosis and 
definition of polypharmacy and the used treatment (if 
applicable) (0–2 points); 6) inclusion and control of all 
the available variables for potential confounders/effect 
modifiers that may had influenced outcome (if applicable) 
(0–2 points); 7) reliability of the information gathered for 
the identification of BD cases/recall bias (0–2 points); 
8) accuracy of the study was to discern between manic, 
hypomanic, mixed, and depressive episodes in BD (0–2 
points); and 9) appropriateness of the number of comorbid 
cases reported as results/sample size (0–2 points). Quality 
rating had 17 as the maximum score.
Studies were also differentiated in the following way: 
1) good quality: most or all criteria being fulfilled, and even 
when they were not met, the study conclusions were thought 
to be very unlikely to alter (range: 10–17 points); 2) moder-
ate quality: some criteria being fulfilled, and when they were 
not met, the study conclusions were thought to be unlikely 
to alter (range: 6–9 points); and 3) poor quality: few criteria 
fulfilled but the conclusions of the study were thought to be 
very likely to alter (range: 0–5 points).
Main clinical features at study
Among others, the following effect moderators were 
accounted for in the analysis: 1) illness duration; 2) ethnicity 
(in order to explore whether ethnic minorities may receive 
different care); 3) any kind of socioeconomic measure or a 
proxy for that, for example, education status; 4) a baseline 
psychiatric symptoms/general functioning score; 5) physi-
cal comorbidity; 6) psychiatric comorbidity; 7) differences 
in setting; 8) year of data collection (to reflect the time 
frame of introduction of different drugs, especially atypi-
cal antipsychotics); 9) geographical region; and 10) study 
design and duration of follow-up (taking into account that 
cross-sectional studies and those with shorter follow-up may 
have higher rates of polypharmacy, as it could be either part 
of cross-titration or transient).
Risk of bias across the studies
Any eventual bias affecting cumulative evidence (eg, publi-
cation bias, selective reporting within studies) was assessed 
through the study evaluation process and accounted in the 
discussion of the present manuscript.
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Results
Study selection
The search in PubMed generated 112 papers and 320 results 
in Scopus. Four hundred eleven additional results were 
obtained through search in Cochrane (n=7), PsycINFO (n=1), 
EMBASE (n=361), or Google Scholar (n=19 – including 
six edited books – out of 8,070 results initially obtained 
before limiting the Google Scholar search strategy to title 
and abstract, excluding patents or citations). Manual search 
allowed the identification of 23 additional results. Overall, 
the combined search strategy yielded a total of 843 results, 
of which 414 were removed after screening because they 
duplicated other articles. Three hundred eleven results were 
further screened; of those latter, 72 were excluded because 
they were not fully meeting the planned inclusion criteria 
(with a special reference to the operative definition of 
polypharmacy and the number of bipolar patients included). 
Therefore, 31 original studies were included in our qualitative 
analysis.3,23–51 Figure 1 provides a synthetic flowchart of the 
multistep selection procedure. Overall, the combined search 
strategy yielded 843 results. Following screening for duplica-
tion, 414 articles were selected. On further evaluation, 311 
studies were eliminated leaving 103 full-text articles. In all, 
72 such articles were then excluded as they did not meet the 
planned inclusion criteria (especially, the operative definition 
of polypharmacy and the number of bipolar patients were 
included). Therefore, 31 original studies were included in 
our qualitative analysis.3,23–51 Figure 1 provides a synthetic 
flowchart of a multistep selection procedure.
Quality score and quality differentiation 
results
Based on the quality differentiation, original studies were 
ranked as follows: poor (n=7, mean total score =3.5), 
moderate (n=13, mean total score =8.2), or good quality 
(n=11, mean total score =12.8). Additional details about 
pivotal cross-sectional, retrospective, and longitudinal studies 
have been outlined in Tables 1–3, respectively.
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e)
 
in
 B
D
-i 
ca
se
s.
T
he
 s
am
pl
e 
in
cl
ud
ed
 a
 t
ot
al
 
of
 2
30
 B
D
-i 
in
pa
tie
nt
s 
ac
ro
ss
 
di
ffe
re
nt
 m
oo
d 
ep
is
od
e 
po
la
ri
ty
 w
er
e.
O
ve
ra
ll,
 c
om
pl
ex
 p
ol
yp
ha
rm
ac
y 
w
as
 
do
cu
m
en
te
d 
in
 8
2 
(3
6%
) 
of
 t
he
 c
as
es
. 
Pa
tie
nt
s 
re
po
rt
ed
 t
ak
in
g 
an
 a
ve
ra
ge
 o
f 
3.
31
±1
.4
6 
ps
yc
ho
tr
op
ic
 a
nd
 5
.9
4±
3.
78
 
no
np
sy
ch
ot
ro
pi
c 
m
ed
ic
at
io
ns
. 
D
at
a 
hi
gh
lig
ht
ed
 t
he
 h
ig
h 
m
ed
ic
at
io
n 
bu
rd
en
 e
xp
er
ie
nc
ed
 
by
 p
at
ie
nt
s 
w
ith
 B
D
, e
sp
ec
ia
lly
 
th
os
e 
BD
-i 
in
pa
tie
nt
s 
w
ho
 a
re
 
ac
ut
el
y 
sy
m
pt
om
at
ic
.
R
el
at
iv
el
y 
sm
al
l 
sa
m
pl
e 
si
ze
 a
nd
 
se
le
ct
io
n 
bi
as
.
i =
0
ii 
=2
iii
 =
2
iv
 =
2
v
 =
2 (
Co
nt
in
ue
d)
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T
ab
le
 2
 (
Co
nt
in
ue
d)
A
ut
ho
r
A
im
/h
yp
ot
he
si
s
Sa
m
pl
e 
si
ze
M
ai
n 
re
su
lt
s
C
on
cl
us
io
ns
Li
m
it
at
io
ns
Q
ua
lit
y 
sc
or
e 
an
d 
di
ffe
re
nt
ia
ti
on
T
ho
se
 c
as
es
 r
ec
ei
vi
ng
 c
om
pl
ex
 
po
ly
ph
ar
m
ac
y 
w
er
e 
si
gn
ifi
ca
nt
ly
 
m
or
e 
lik
el
y 
to
 b
e 
w
om
en
 a
nd
 t
o 
be
 p
re
sc
ri
be
d 
w
ith
 a
nt
id
ep
re
ss
an
ts
, 
be
nz
od
ia
ze
pi
ne
s,
 a
nd
 s
tim
ul
an
ts
, e
ve
n 
af
te
r 
co
nt
ro
lli
ng
 fo
r 
m
oo
d 
ep
is
od
e 
po
la
ri
ty
. L
ith
iu
m
 w
as
 p
re
sc
ri
be
d 
as
 p
ar
t 
of
 p
ol
yp
ha
rm
ac
y 
in
 1
3%
 o
f t
he
 c
as
es
.
v
i =
2
v
ii 
=0
v
iii
 =
2
iX
 =
1
T
ot
al
 =
13
O
ve
ra
ll 
qu
al
ity
 =
 
go
od
.
H
un
g 
et
 a
l28
T
he
 T
ai
w
an
es
e 
N
at
io
nw
id
e 
Ps
yc
hi
at
ri
c 
in
pa
tie
nt
 M
ed
ic
al
 
C
la
im
s 
(2
00
0–
20
07
) 
w
er
e 
us
ed
 
to
 e
xa
m
in
e 
pr
es
cr
ip
tio
n 
fo
r 
m
oo
d 
st
ab
ili
ze
rs
, a
nt
ip
sy
ch
ot
ic
s,
 
an
d 
an
tid
ep
re
ss
an
ts
 a
m
on
g 
re
ce
nt
ly
 d
is
ch
ar
ge
d 
pa
tie
nt
s 
w
ith
 B
D
. O
pe
ra
tiv
e 
de
fin
iti
on
 
of
 p
ol
yp
ha
rm
ac
y 
w
as
 t
w
o 
or
 m
or
e 
ps
yc
ho
tr
op
ic
 
m
ed
ic
at
io
ns
.
O
ut
 o
f 5
,4
49
 B
D
 p
at
ie
nt
s,
 
5,
15
5 
(9
5%
) 
w
er
e 
BD
-i.
 A
m
on
g 
th
em
, n
=2
,9
23
 (5
7%
) p
re
se
nt
ed
 
w
ith
 a
 m
an
ic
 e
pi
so
de
, 1
,0
76
 
(2
1%
) 
de
pr
es
se
d 
ep
is
od
e,
 7
68
 
(1
5%
) 
m
ix
ed
 e
pi
so
de
, a
nd
 3
70
 
(7
%
) 
un
sp
ec
ifi
ed
 e
pi
so
de
.
Fo
r 
3,
85
3 
(7
1%
) 
pa
tie
nt
s,
 p
re
sc
ri
pt
io
ns
 
in
vo
lv
ed
 b
et
w
ee
n-
cl
as
s 
po
ly
ph
ar
m
ac
y,
 
an
d 
fo
r 
94
1 
(1
7%
), 
pr
es
cr
ip
tio
ns
 
co
nt
ai
ne
d 
w
ith
in
-c
la
ss
 p
ol
yp
ha
rm
ac
y.
M
oo
d 
st
ab
ili
ze
rs
 a
cc
ou
nt
ed
 fo
r 
a 
m
aj
or
ity
 o
f p
ol
yp
ha
rm
ac
y 
am
on
g 
ho
sp
ita
liz
ed
 p
at
ie
nt
s,
 w
hi
ch
 r
at
es
 
w
er
e 
pa
rt
ic
ul
ar
ly
 h
ig
h 
in
 c
as
e 
of
 
be
tw
ee
n-
cl
as
s 
pr
es
cr
ip
tio
ns
. A
s 
pr
om
pt
ed
 o
ut
 b
y 
th
e 
au
th
or
s 
th
em
se
lv
es
, t
hi
s 
is
 c
on
tr
as
t 
to
 
th
e 
us
ua
l fi
nd
in
g 
re
po
rt
ed
 b
y 
st
ud
ie
s 
ca
rr
ie
d 
on
 o
ut
pa
tie
nt
 
sa
m
pl
es
 o
f B
D
, e
sp
ec
ia
lly
 B
D
-ii
 
w
om
en
, w
he
re
as
 a
nt
id
ep
re
ss
an
ts
 
ar
e 
of
te
n 
pr
es
cr
ip
tio
n 
in
 t
he
 
co
nt
ex
t 
of
 p
ol
yp
ha
rm
ac
y.
A
lm
os
t 
on
ly
 B
D
-i 
m
an
ic
 in
pa
tie
nt
s 
w
er
e 
in
cl
ud
ed
. 
Pe
rm
is
si
ve
 c
ri
te
ri
on
 
fo
r 
po
ly
ph
ar
m
ac
y 
(y
et
 a
cc
ur
at
e 
di
st
in
ct
io
n 
be
tw
ee
n 
w
ith
in
- 
an
d 
be
tw
ee
n-
cl
as
s 
po
ly
ph
ar
m
ac
y 
pr
es
cr
ip
tio
ns
).
i =
1
ii 
=2
iii
 =
2
iv
 =
2
v
 =
2
v
i =
0
v
ii 
=0
v
iii
 =
0
iX
 =
0
T
ot
al
 =
9
O
ve
ra
ll 
qu
al
ity
 =
 
m
od
er
at
e.
Ba
ek
 e
t 
al
29
T
o 
re
tr
os
pe
ct
iv
el
y 
as
se
ss
 t
he
 
pa
tt
er
n 
of
 p
ha
rm
ac
ot
he
ra
py
 
by
 e
pi
so
de
 t
yp
e 
in
 K
or
ea
n 
BD
 p
at
ie
nt
s 
an
d 
ra
te
s 
of
 
co
nc
or
da
nc
e 
w
ith
 v
ar
yi
ng
 
in
te
rn
at
io
na
l s
ta
nd
ar
d 
tr
ea
tm
en
t 
gu
id
el
in
es
.
T
he
 s
am
pl
e 
in
cl
ud
ed
 B
D
-i 
ca
se
s 
(n
=9
90
; o
f w
ho
m
, 
n=
48
0 
be
in
g 
cu
rr
en
tly
 m
an
ic
 
in
pa
tie
nt
s,
 n
=1
13
 b
ei
ng
 
de
pr
es
si
ve
 in
pa
tie
nt
s,
 a
nd
 
n=
39
7 
be
in
g 
ou
tp
at
ie
nt
s)
 a
nd
 
BD
-ii
 c
as
es
 (
to
ta
l n
=4
57
, o
f 
w
ho
m
 d
ep
re
ss
iv
e 
in
pa
tie
nt
s 
w
er
e 
n=
19
0 
an
d 
ou
tp
at
ie
nt
s 
w
er
e 
n=
26
7)
.
T
he
 o
ve
ra
ll 
co
nc
or
da
nc
e 
ra
te
 o
f 
pr
es
cr
ip
tio
ns
 fo
r 
m
an
ic
 in
pa
tie
nt
s 
to
 
th
e 
gu
id
el
in
es
 w
as
 h
ig
he
r 
an
d 
re
la
tiv
el
y 
m
or
e 
co
ns
is
te
nt
 (
43
.8
%
–4
8.
7%
) 
co
m
pa
re
d 
to
 t
ha
t 
fo
r 
de
pr
es
si
ve
 
in
pa
tie
nt
s 
(1
8.
6%
–4
6.
9%
).
Po
ly
ph
ar
m
ac
y 
w
as
 a
 c
om
m
on
 
re
as
on
 o
f n
on
co
nc
or
da
nc
e 
to
w
ar
d 
va
ry
in
g 
tr
ea
tm
en
t 
gu
id
el
in
es
 fo
r 
BD
, e
sp
ec
ia
lly
 fo
r 
th
os
e 
BD
-ii
 d
ep
re
ss
ed
 p
at
ie
nt
s 
re
ce
iv
in
g 
SG
A
(s
) 
to
o.
R
et
ro
sp
ec
tiv
e 
de
si
gn
 
of
 t
he
 s
tu
dy
; p
ar
tia
l 
co
nt
ro
l f
or
 p
ot
en
tia
l 
co
nf
ou
nd
in
g 
fa
ct
or
s.
i =
1
ii 
=2
iii
 =
1
iv
 =
2
v
 =
0
v
i =
0
v
ii 
=1
v
iii
 =
2
iX
 =
1
T
ot
al
 =
10
O
ve
ra
ll 
qu
al
ity
 =
 
go
od
.
A
bb
re
vi
at
io
ns
: B
D
, b
ip
ol
ar
 d
is
or
de
r;
 N
O
S,
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
; F
, f
em
al
e;
 M
, m
al
e;
 S
G
A
, s
ec
on
d-
ge
ne
ra
tio
n 
an
tip
sy
ch
ot
ic
.
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T
ab
le
 3
 e
ss
en
tia
l p
ro
sp
ec
tiv
e 
st
ud
ie
s
A
ut
ho
r
A
im
/h
yp
ot
he
si
s
Sa
m
pl
e 
si
ze
M
ai
n 
re
su
lt
s
C
on
cl
us
io
ns
Li
m
it
at
io
ns
Q
ua
lit
y 
sc
or
e 
an
d 
di
ffe
re
nt
ia
ti
on
H
ae
be
rl
e 
et
 a
l25
T
o 
lo
ng
itu
di
na
lly
 
fo
llo
w
 e
ur
op
ea
n 
in
pa
tie
nt
s 
w
ith
 a
 
di
ag
no
si
s 
of
 b
ip
ol
ar
 
de
pr
es
si
on
 o
ve
r 
a 
15
-y
ea
r 
fo
llo
w
-u
p 
pe
ri
od
 (
19
94
–2
00
9)
.
A
 t
ot
al
 2
,2
46
 in
pa
tie
nt
s,
 b
ot
h 
se
x 
an
d 
ag
e 
18
 o
r 
ol
de
r 
w
er
e 
in
cl
ud
ed
 in
 t
he
 p
re
se
nt
 s
tu
dy
.
A
nt
id
ep
re
ss
an
ts
 w
er
e 
th
e 
m
os
t 
fr
eq
ue
nt
ly
 p
re
sc
rib
ed
 c
la
ss
 o
f 
dr
ug
s 
gi
ve
n 
in
 c
om
bi
na
tio
n.
 
O
la
nz
ap
in
e 
pl
us
 fl
uo
xe
tin
e 
co
m
bi
na
tio
n 
w
as
 fo
un
d 
to
 b
e 
pr
es
cr
ib
ed
 o
nl
y 
in
 v
er
y 
fe
w
 
pa
tie
nt
s, 
as
 it
 w
as
 th
e 
ca
se
 fo
r 
bu
pr
op
io
n 
(w
hi
ch
 m
ay
 r
efl
ec
t 
a 
di
ffe
re
nt
ia
l p
re
sc
rip
tio
n 
tr
en
d 
co
m
pa
re
d 
to
 N
or
th
 A
m
er
ic
a 
w
ith
in
 th
e 
pe
rio
d 
at
 s
tu
dy
). 
Q
ue
tia
pi
ne
 w
as
 fo
un
d 
to
 b
e 
th
e 
se
co
nd
 m
os
t f
re
qu
en
tly
 
pr
es
cr
ib
ed
 s
ub
st
an
ce
 fo
r 
bi
po
la
r 
de
pr
es
sio
n 
du
rin
g 
th
e 
pe
rio
d 
of
 2
00
6–
20
09
.
O
ve
ra
ll,
 t
he
 p
re
se
nt
 s
tu
dy
 s
ho
w
ed
 t
ha
t 
m
ul
tip
le
 c
om
bi
na
tio
ns
 o
f p
sy
ch
ot
ro
pi
c 
dr
ug
s 
is
 r
ou
tin
el
y 
pr
es
cr
ib
ed
 in
 t
he
 
cl
in
ic
al
 r
ou
tin
e,
 in
cl
ud
in
g 
an
tid
ep
re
ss
an
t, 
de
sp
ite
 t
he
ir
 c
on
tr
ov
er
si
al
 r
ol
e 
in
 b
ip
ol
ar
 
de
pr
es
si
on
. T
he
 t
re
nd
 o
f s
ec
on
d-
ge
ne
ra
tio
n 
an
tip
sy
ch
ot
ic
 c
om
bi
na
tio
ns
 
w
as
 a
ls
o 
st
ea
di
ly
 in
cr
ea
si
ng
 o
ve
r 
th
e 
tim
e 
w
ith
in
 t
he
 c
ov
er
ed
 p
er
io
d 
of
 t
im
e.
 O
nl
y 
33
7 
(1
5%
) 
pa
tie
nt
s 
re
ce
iv
ed
 m
on
ot
he
ra
py
 
at
 t
im
e 
of
 a
ss
es
sm
en
t, 
w
ith
 v
ir
tu
al
ly
 n
on
e 
of
 t
he
m
 b
ei
ng
 m
ed
ic
at
io
n 
fr
ee
 a
t 
tim
e 
of
 
ho
sp
ita
liz
at
io
n.
 F
in
al
ly
, l
ith
iu
m
 w
as
 t
he
 
le
ss
 c
om
m
on
 d
ru
g 
us
ed
 in
 c
om
bi
na
tio
n 
w
ith
 a
ny
 o
th
er
 c
la
ss
 o
f s
ub
st
an
ce
 (
n=
74
1 
or
 3
3%
 o
f t
he
 c
as
es
).
Pe
rm
is
si
ve
 o
pe
ra
tiv
e 
de
fin
iti
on
 
of
 p
ol
yp
ha
rm
ac
y 
(t
w
o 
or
 m
or
e 
cl
as
s 
of
 p
sy
ch
ot
ro
pi
c 
su
bs
ta
nc
es
). 
La
ck
 o
f a
dd
iti
on
al
 d
em
og
ra
ph
ic
 
or
 c
lin
ic
al
 s
tr
at
ifi
ca
tio
ns
, i
nc
lu
di
ng
 
BD
 t
yp
e.
i =
1
ii 
=2
iii
 =
1
iv
 =
2
v
 =
0
v
i =
0
v
ii 
=1
v
iii
 =
2
iX
 =
1
T
ot
al
 =
10
O
ve
ra
ll 
qu
al
ity
 =
 
go
od
.
Ba
ue
r 
et
 a
l34
T
o 
pr
os
pe
ct
iv
el
y 
do
cu
m
en
t 
th
e 
na
tu
ra
lis
tic
 
pr
es
cr
ip
tio
n 
tr
en
ds
 
of
 B
D
 p
at
ie
nt
s 
in
 
th
e 
U
SA
, G
er
m
an
y,
 
C
an
ad
a,
 a
nd
 
el
se
w
he
re
.
D
at
a 
on
 4
50
 c
as
es
 o
f B
D
 w
er
e 
co
lle
ct
ed
 o
ve
r 
a 
pe
ri
od
 o
f 
ap
pr
ox
im
at
el
y 
6 
m
on
th
s.
 B
D
-i 
ca
se
s 
w
er
e 
n=
27
2 
(6
0%
), 
BD
-ii
 
n=
15
7 
(3
5%
), 
an
d 
BD
-N
O
S 
=1
7 
(5
%
).
Po
ly
ph
ar
m
ac
y 
(n
am
el
y 
th
e 
co
nc
om
ita
nt
 u
se
 o
f a
t 
le
as
t 
tw
o 
ps
yc
ho
tr
op
ic
 m
ed
ic
at
io
ns
 
of
 e
ith
er
 t
he
 s
am
e 
or
 d
iff
er
en
t 
cl
as
se
s)
 w
as
 r
ec
or
de
d 
in
 u
p 
to
 
75
%
 o
f t
he
 c
as
es
. S
pe
ci
fic
al
ly
, 
su
st
ai
ne
d 
po
ly
ph
ar
m
ac
y 
re
ga
rd
ed
 3
53
 (
78
.4
%
) 
of
 
pa
tie
nt
s 
fo
r 
at
 le
as
t 
$
50
%
 o
f 
da
ys
. O
ve
ra
ll 
m
ea
n 
fo
llo
w
-u
p 
w
as
 2
22
 d
ay
s.
O
ve
ra
ll,
 m
os
t 
of
 t
he
 p
at
ie
nt
s 
re
ce
iv
ed
 
m
oo
d-
st
ab
ili
ze
r 
dr
ug
s.
 Y
et
, t
ho
ug
h 
m
os
t 
pa
tie
nt
s 
w
er
e 
re
ce
iv
in
g 
po
ly
ph
ar
m
ac
y,
 
th
er
e 
w
er
e 
no
 p
re
do
m
in
an
t 
dr
ug
 
re
gi
m
en
s 
ev
en
 a
m
on
g 
th
os
e 
ta
ki
ng
 s
ta
bl
e 
co
m
bi
na
tio
ns
. M
os
t 
pa
tie
nt
s 
w
ith
 s
ta
bl
e 
co
m
bi
na
tio
ns
 t
oo
k 
a 
re
la
tiv
el
y 
sm
al
l 
nu
m
be
r 
of
 d
ru
gs
 d
ai
ly
. 
N
o 
st
ra
tifi
ca
tio
n 
w
as
 d
oc
um
en
te
d 
fo
r 
cu
rr
en
t 
m
oo
d 
ph
as
e 
of
 B
D
.
i =
1
ii 
=2
iii
 =
2
iv
 =
2
v
 =
1
v
i =
1
v
ii 
=0
v
iii
 =
2
iX
 =
0
T
ot
al
 =
11
O
ve
ra
ll 
qu
ali
ty
 =
 g
oo
d.
Ba
ue
r 
et
 a
l51
T
o 
an
al
yz
e 
th
e 
re
gu
la
ri
ty
 in
 
da
ily
 d
os
ag
e 
of
 
an
tid
ep
re
ss
an
ts
 t
ak
en
 
by
 B
D
 p
at
ie
nt
s 
an
d 
fa
ct
or
s 
as
so
ci
at
ed
 
w
ith
 ir
re
gu
la
ri
ty
.
T
he
 s
am
pl
e 
in
cl
ud
ed
 1
44
 B
D
 
pa
tie
nt
s:
 B
D
-i,
 n
=6
7;
 B
D
-ii
, 
n=
65
; a
nd
 B
D
-N
O
S,
 n
=1
0.
 
Fe
m
al
es
 w
er
e 
n=
10
8 
(o
r 
75
%
 
of
 t
he
 s
am
pl
e)
. P
ol
yp
ha
rm
ac
y 
w
as
 d
efi
ne
d 
as
 t
he
 u
se
 o
f t
w
o 
or
 m
or
e 
ps
yc
ho
tr
op
ic
 d
ru
gs
 a
t 
on
ce
. R
eg
ul
ar
ity
 w
as
 m
ea
su
re
d 
us
in
g 
th
e 
A
pn
en
, w
hi
ch
 is
 t
he
 
te
nd
en
cy
 t
ha
t 
va
lu
es
 w
ith
in
 a
 
tim
e 
se
ri
es
 r
em
ai
n 
th
e 
sa
m
e 
on
 
th
e 
in
cr
em
en
ta
l c
om
pa
ri
so
ns
.76
T
ot
al
 n
um
be
r 
of
 p
sy
ch
ot
ro
pi
c 
m
ed
ic
at
io
ns
 w
as
 s
ig
ni
fic
an
tly
 
as
so
ci
at
ed
 w
ith
 ir
re
gu
la
ri
ty
 
(P
=0
.0
05
), 
as
 it
 w
as
 “
pi
ll 
bu
rd
en
” 
(P
=0
.0
05
), 
an
d 
de
pr
es
si
on
 (
P=
0.
01
5)
, N
ei
th
er
 
th
e 
pe
rc
en
ta
ge
 o
f d
ay
s 
m
is
si
ng
 
do
se
s 
no
r 
th
e 
dr
ug
 h
ol
id
ay
s 
w
er
e 
as
so
ci
at
ed
 w
ith
 a
ny
 
de
m
og
ra
ph
ic
 o
f c
lin
ic
al
 fa
ct
or
s.
ir
re
gu
la
ri
ty
 in
 d
ai
ly
 d
os
ag
e 
is
 c
om
m
on
, 
de
sp
ite
 a
 lo
w
 p
er
ce
nt
ag
e 
of
 d
ay
s 
m
is
si
ng
. 
D
ai
ly
 ir
re
gu
la
ri
ty
 in
 d
ru
g 
do
sa
ge
 m
ay
 b
e 
m
or
e 
de
pe
nd
en
t 
on
 t
he
 in
di
vi
du
al
 r
at
he
r 
th
an
 o
n 
a 
sp
ec
ifi
c 
dr
ug
.
R
el
at
iv
el
y 
sm
al
l s
am
pl
e 
si
ze
 
an
d 
re
la
tiv
el
y 
sh
or
t 
fo
llo
w
-u
p 
(1
00
 d
ay
s)
. P
er
m
is
si
ve
 c
ri
te
ri
on
 o
f 
po
ly
ph
ar
m
ac
y.
i =
1
ii 
=2
iii
 =
1
iv
 =
1
v
 =
1
v
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Conceptual and operative definitions of 
polypharmacy across selected studies
Polypharmacy has been defined in at least 24 distinct con-
ceptual ways, with “medication nonmatching a diagnosis” 
being the most commonly adopted conceptual definition,52 
capturing what could be both inappropriate therapy, that is, 
too many medications, and “evidence-based therapy that is 
inappropriate.”53 The operative definitions of polypharmacy 
are also elusive and/or too broad,54–56 with the most com-
monly used definitions of psychiatric polypharmacy being 
the “use of two or more psychiatric medications in the same 
patient,”2,55 rather than “use of two or more medications of 
the same class or equivalent pharmacologic action to treat 
the same condition [BD].”57 Nonetheless, “current use of 
four more psychotropic medications at once” was the most 
reliable operative definition for “complex polypharmacy” 
across the most pivotal studies.3,23,27,40,42
Prevalence rates of polypharmacy in BD
A post hoc3 report based on the baseline data of the STEP-BD 
study10 indicated that only 12% of the patients (n=472 out 
4,035) were taking none of the accounted medication at study 
entry, in contrast to 839 (21%) taking one vs 1,130 (28%) 
receiving two medications vs 883(22%) on three vs 711 
(18%) taking four or more medications (complex polyphar-
macy). Of 2,159 females (53.5% of the total sample), 21% of 
whom (n=446) were received complex polypharmacy. With 
respect to the diagnostic type of BD, 2,666 patients were 
BD-I, of whom, 510 received complex polypharmacy, 2,156 
received less than four medications; 1,084 were BD-II (com-
plex polypharmacy, n=171 vs 913 not receiving complex 
polypharmacy); and 285 BD-not otherwise specified (NOS) 
cases, of whom just 30 received complex polypharmacy vs 
255 who did not.
The operative definition of complex polypharmacy 
adopted for the STEP-BD post hoc3 was modified by inde-
pendent authors conducting a chart-review study on 230 
BD-I patients (of whom, 134 or 58% females) admitted to 
an inpatient or partial hospitalization, herein encompassing 
all classes of psychotropic and nonpsychotropic medica-
tions in order to better reflect routine clinical prescriptions 
for BD patients.27 In all, 186 of the cases (81% of the total 
sample) received complex polypharmacy, while 122 (53%) 
reported taking medication for nonpsychiatric purposes. 
Polarity of mood episode on admission was as follows: 
depressed, n=85 (37%); manic, n=96 (42%); mixed state, 
n=44 (19%); and unspecified, n=5 (2%). Among those treated 
with pharmacotherapy for BD, patients reported taking an 
average of 3.31±1.46 psychotropic medications at the time 
of hospitalization. Average total medication usage (includ-
ing both psychotropic and nonpsychotropic medications) 
was 5.94±3.78. One hundred twenty-six cases (55% of the 
sample) reported taking three or more psychotropic medica-
tions at the time of hospitalization, and 82 cases (36%) of the 
study met the operational criteria for complex polypharmacy. 
This figure represents 44% of those receiving any pharma-
cotherapy for BD at the time of hospital admission. Overall, 
even after accounting for 20% of patients who were not 
engaged in any pharmacologic treatment prior to hospitaliza-
tion, 55% were on three or more psychotropic medications 
at the time of hospital admission and 36% were on four or 
more. The latter figure is exactly double than the rate reported 
from the outpatient STEP-BD sample,3 although more con-
sistent with rates of polypharmacy reported in voluntary BD 
registries.41 Concordant with previous reports,58,59 additional 
analyses carried out by Weinstock et al27 revealed that the 
average number of prescriptions almost doubled (from 3.3 to 
5.9) when both psychotropic and nonpsychotropic medica-
tions were taken into account. The authors themselves also 
acknowledged that the discrepancy seen with respect to the 
STEP-BD post hoc report3 may be attributable to different 
operational criteria for complex polypharmacy, differential 
settings, and proportion of BD-I cases.
Data from the Arzneimittelüberwachung in der Psy-
chiatrie (AMSP) European drug surveillance program60,61 
involving 2,246 cases of bipolar depression followed over a 
16-year period (1994–2009)25 just relied on a “permissive” 
operative definition of polypharmacy, namely the use of two 
or more class of psychotropic substances. The prevalence 
rates of polypharmacy in European patients were therefore 
strikingly high, with almost 85% of the cases receiving 
polypharmacy in contrast to only 337 cases (or 15% of the 
total) receiving monotherapy (herein defined as the use 
of antidepressants or antipsychotics or anticonvulsants or 
lithium, including within-class prescriptions). Data about 
the practice of complex polypharmacy in European cases 
experiencing a current bipolar depressive episode were 
nonetheless made available by a 2012 report based on 2,231 
inpatients (unspecified subtypes proportions) followed up in 
the context of the AMSP program between 1994 and 2009, 
which documented 137 patients (6.4% of the total) treated 
with at least four different psychotropic drugs at once, with 
rates steadily increasing, especially after year 2006.33 Data 
about the practice of polypharmacy in Eastern European and 
Middle East patients just rely on post hoc cross-sectional 
analysis of the baseline records of a large (n=894) prospective 
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study carried on manic patients prescribed with olanzapine 
(n=569 or 63.64%) or not (n=325 or 36.35%). While these 
data reflect a special population at study, the rates of polyp-
harmacy were nonetheless very high (n=719 or 80.4%), 
although the authors adopted a permissive criterion of two or 
more psychotropic drugs at once.31 Slightly lower prevalence 
rates in manic patients were also documented in Taiwanese 
inpatients approximately assessed within the same period 
(years 2000–2007). Specifically, out of 5,449 BD patients, 
5,155 (95%) were BD-I cases, of whom 2,923 (57%) present-
ing with a manic episode at the time of hospitalization, 1,076 
(21%) with depressed episode, 768 (15%) mixed episode, 
and 370 (7%) unspecified episode. Between-class vs within-
class polypharmacy (according to the permissive criterion of 
two or more psychotropic drugs at once) occurred in 3,853 
(71%) vs 941 (17%) patients, respectively.28
Prescription trends and main clinical 
features associated with polypharmacy 
in BD
Quality receiver–operating characteristics post hoc analysis 
of the baseline records of the STEP-BD study3 also revealed 
that BD subjects had a 64% risk for receiving complex 
polypharmacy if they had ever taken any second-generation 
antipsychotic (SGA) drug, had six or more lifetime depres-
sive episodes, ever attempted suicide (complex polyphar-
macy cases, n=686, vs noncomplex polypharmacy cases, 
n=1,105; P#0.0001; Cohen’s d=0.05), and had an annual 
income of US$75,000 or higher (complex polypharmacy 
cases, n=158, vs noncomplex polypharmacy cases, n=747; 
P= nonsignificant [ns]; d=0.00). In contrast, complex polyp-
harmacy was least often associated with lithium (n=41 vs 
225 receiving lithium but not complex polypharmacy; 
d=0.03), divalproex (251 vs 934 noncomplex polypharmacy 
cases; d=0.11), and carbamazepine (219 vs n=548 noncom-
plex polypharmacy cases; d=0.13), whereas complex polyp-
harmacy was most often associated with SGA use (complex 
polypharmacy cases, n=482, vs noncomplex polypharmacy 
cases, n=780; d=0.74), with antidepressants (684 vs n=1,251 
noncomplex polypharmacy cases; d=0.78 – which is actually 
the largest effect size reported by the authors in their analy-
ses). Contrary to expectations, a history of psychosis (com-
plex polypharmacy cases, n=96, vs noncomplex polypharmacy, 
n=309; P=0.001; d=0.02), age at onset (complex polypharmacy 
mean age =16.4±3.3 vs noncomplex polypharmacy mean 
age of onset of 16.2±3.6; P=ns; d=0.03), BD-I vs BD-II 
subtype (no contrasts, P-value or d value reported), prior to 
hospitalization (no contrasts, P-value or d value reported), 
current illness state (no contrasts, P-value or d value 
reported), and history of substance use disorder (SUD) 
(complex polypharmacy, n=84, vs noncomplex polyphar-
macy, n=461; P=ns; d=0.05) did not significantly alter the 
risk profiles for receiving complex regimens, although con-
cerns about the chance of a Berkson’s bias could be raised 
in these regards. Accounting of additional psychotropic and 
nonpsychotropic medications beyond the sole, seven-core 
medications regarded by the STEP-BD study (namely lith-
ium, divalproex, carbamazepine, lamotrigine, and other 
anticonvulsants without definitely established thymoleptic 
properties as topiramate, gabapentin; oxcarbazepine, as well 
as SGA or any antidepressant) allowed Weinstock et al to 
provide additional insights about the clinical correlates of 
complex polypharmacy in BD.27 Overall, according to this 
latter report, those BD-I cases receiving complex polyphar-
macy were significantly more likely to be female, depressed, 
have a comorbid anxiety disorder, and have a history of 
suicide attempt. Conversely, those receiving complex polyp-
harmacy were significantly less likely to be manic and present 
with active psychosis at the time of hospital admission. 
Noteworthy, given that medication decisions may be espe-
cially driven by mood episode polarity, the authors decided 
on a priori basis to treat mood episode polarity as a covariate 
in any multivariate analysis to evaluate the demographic and 
clinical factors associated with complex polypharmacy and 
patterns of specific medication use, over and above any 
shared variance with mood episode. Therefore, controlling 
for mood episode polarity, female sex, B (standard error 
[SE])=0.58 (0.29), χ2(1)=3.88, P=0.049, OR =1.78; anxiety 
disorder comorbidity, B (SE)=0.72(0.32), χ2(1)=5.18, 
P=0.023, OR =2.05; and history of suicide attempt, 
B (SE)=0.79(0.34), χ2(1)=5.60, P=0.018, OR =2.21 remained 
significant predictors of complex polypharmacy for BD-I, 
whereas psychosis did not, B (SE)=−0.50 (0.32), χ2(1)=2.40, 
P=0.121, OR =0.61. Each psychotropic medication class was 
significantly associated with increased likelihood of complex 
polypharmacy. With respect to pattern of medication use by 
mood episode polarity, there was no statistically significant 
difference between depressed and mixed polarity patients 
(all P=0.11–0.94). As such, the authors combined these latter 
groups for purposes of comparison against patients presenting 
with pure mania. Use of antidepressants was significantly 
higher in the depressed/mixed polarity patients in comparison 
to patients presenting with pure mania (45% vs 20%; 
χ2(1)=15.49, P,0.001). This pattern of effects held for the 
use of selective serotonin reuptake inhibitors (26% vs 12%; 
χ2(1)=7.64, P=0.006), serotonin norepinephrine reuptake 
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inhibitors (10% vs 2%; χ2(1)=5.65, P=0.017), and all other 
antidepressants (19% vs 7%; χ2(1)=5.93, P=0.015). Use of 
benzodiazepines (BDZs) was also significantly higher in the 
depressed/mixed polarity patients vs those presenting with 
mania (47% vs 33%; χ2(1)=4.42, P=0.036), while use of all 
remaining medications (ie, lithium, anticonvulsants, antip-
sychotics, stimulants, and hypnotics) did not differ as a 
function of episode polarity (all P-values=0.08–0.90). In 
addition, corresponding information about the use of varying 
classes of antidepressants for European BD inpatients receiv-
ing polypharmacy (yet herein adopting a permissive criterion 
of two or more drugs within different classes at once) was 
provided by Haeberle et al in 2012.25 Olanzapine plus fluox-
etine combination was found to be prescribed only in very 
few patients, as it was the case for the norepinephrine dop-
amine reuptake inhibitor bupropion, also possibly due to 
different drug policies and approval dates compared to the 
USA, despite the SGA quetiapine was found to be the second 
most frequently prescribed adjunctive therapy for bipolar 
depression during the period covered by the study, years 
2006–2009, whereas lithium was the less common drug used 
in combination with any other class of substance (n=741 or 
33% of the cases).25 Owing to evidence pointing out that less 
than one-third of BD patients in the USA and about half of 
those in Europe received monotherapy,3,62–65 Bauer et al 
planned a long-term naturalistic study in which patients with 
BD self-recorded mood, sleep, and drugs taken daily over a 
period of ∼6 months with the ultimate aim to further char-
acterize the drug treatment patterns in 450 BD cases. Of these 
latter BD cases, 272 were BD-I cases (60%), 157 BD-II 
(35%), and 17 BD-NOS cases (5%). Noteworthy, the study 
adopted a permissive operative criterion for polypharmacy 
defined as the use of two or more psychotropic drugs at 
once.34 Drug load was measured using the methodology 
developed by the World Health Organization (WHO) based 
on a measure of equipotency known as the defined daily 
dose.66 Overall, 315 or 70% of the cases resided in the USA; 
n=53 or 11.8% resided in Germany; n=45 or 10% resided in 
Canada; and 37 or 8.2% resided elsewhere. Enrolled patients 
returned a total of 99,895 days of data (mean 222.0 days), 
with the most frequently taken drugs being mood stabilizers 
and 353 patients (78.4% of the total) taking a stable drug 
combination for half of days or longer. The majority of 
patients were taking polypharmacy, including 75% of those 
with a stable combination. Only a small number of drugs 
were commonly taken within each medication class, but there 
were a large number of unique drug combinations: 52 by 
medication class and 231 by specific drugs. Eighty percentage 
of patients with a stable combination were taking three or 
less drugs daily, although no specific report was documented 
in relationship with polypharmacy and lifetime hospitaliza-
tion. Two previous chart-review studies on 457 BD-I cases 
suggested a positive correlation between the total number of 
current psychotropic medications and the number of hospi-
talization for depressive episodes, though not with suicidal 
attempt, neither lithium nor carbamazepine use in case of 
hospitalization due to mania.40,41 Finally, while most cross-
sectional and longitudinal studies on the relationship between 
polypharmacy and the clinical features and/or prescription 
trends primarily focused on symptomatic cases of BD, evi-
dence focusing just on 80 euthymic patients documented that 
those subjects self-reporting normal mood over a period of 
3 consecutive months or longer usually received a lower 
number of drugs compared to nonlasting cases of euthymia, 
though a “selection by indication bias” would be prompted 
out considering that those cases receiving polypharmacy may 
already include the most severe and possibly rapid-cycling 
course cases of BD.42
Personality features associated with polypharmacy 
in BD
A retrospective chart review of 89 treatment-seeking BD 
outpatients (F:M =48:41) assessed by the means of the 
revised NEO Five Factor Personality Inventory67 about five 
personality dimensions, including neuroticism (the tendency 
to experience negative affect), extraversion (a tendency 
toward energy, positive emotions, and stimulation-seeking), 
conscientiousness (a tendency toward self-discipline and 
dutiful behavior), openness to experience (sometimes 
described as intellectual curiosity), and agreeableness 
(a tendency to be cooperative and compassionate) took into 
account 41 commonly prescribed psychotropic medications 
grouped in six classes (mood stabilizers, antidepressants, 
dopamine blockers, anxiolytic/sedative hypnotics, stimu-
lants, and other) splitting the samples based on mean psy-
chotropic medication use as follows: for current psychotropic 
medications: #3= low vs $4= high and for lifetime medica-
tions: #10= low vs $11= high. The subgroup with low open-
ness had significantly more current psychotropic medications 
(3.7±1.9) than patients in the higher distribution of openness 
scores (2.8±1.8, P,0.005). There was no other comparison 
that reached statistical significance for either current or 
lifetime medications. Nonetheless, the subgroup using 18 
or more lifetime psychotropic medications had significantly 
lower extraversion (21.8±8.9 vs 25.4±7.6, P#0.005) and 
lower conscientiousness (21.9±8.2 vs 27.9±8.2, P,0.001) 
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than those reporting lifetime usage of fewer than controls. 
Remarkably, the authors did not examine whether the dura-
tion of exposure to an ineffective medication would be cor-
related to reluctance to discontinue the ineffective agent, 
so that at present, conclusive statement about the potential 
moderator effect of personality traits in BD as measured by 
the means of the NEO Five Factor Personality Inventory 
could not be drawn.
Polypharmacy in suicidal behavior bipolar patients
Although different studies also accounted for suicidal cases 
of BD, the only quantitative evidence specifically addressing 
this issue involved 169 BD outpatients (most of whom being 
BD-I cases, n=145 or 85.7%) and used a permissive criterion 
for polypharmacy (two or more psychotropic medications), 
which actually occurred in 142 (84%) of the cases in contrast 
to just 27 patients (16%) receiving monotherapy. Polyphar-
macy with three or more medications occurred in 31 (19%) 
of the cases. Overall, rapid-cycling course was seen in up to 
26.9% of the cases, which is a quite high rate, especially tak-
ing into account that most of the suicidal behavior outpatients 
were BD-I rather than BD-II cases.
Antipsychotic drugs prescription rates and 
polypharmacy in BD
The evidence about the use of antipsychotic polypharmacy in 
BD is also scarce and prone to publication bias considering 
the relatively novel introduction of most SGA drugs or their 
latter approval for BD and/or popularity as off-label prescrip-
tions for BD patients, which nonetheless increased over the 
time.68 Also, different prescription trends for SGA vs first-
generation antipsychotics (FGAs) may depend on the geo-
graphical setting and resource settings, as Eastern European 
BD inpatients were less frequently prescribed with SGAs in 
comparison to their Western counterpart, with a 2010 report 
documenting 23.8% of them receiving two antipsychotics vs 
28.6% receiving “complex antipsychotic polypharmacy.”48 
Indeed, much larger samples of BD patients prescribed with 
antipsychotic polypharmacy were documented by North 
American studies. For example, retrospective data on mul-
tistate Medicaid population for years 1998–2003 regarded 
8,489 BD patients (unspecified proportion of BD subtypes), 
of whom 623 (7.3%) took antipsychotic polypharmacy 
(one or more antipsychotic drug) for at least 60 consecutive 
months (accountable SGAs at the time were olanzapine, 
quetiapine, risperidone, and the atypical antipsychotic 
clozapine).44 Additionally, cross-sectional information on 
antipsychotic polypharmacy based on 1998 data (accounted 
SGAs could be olanzapine, quetiapine, risperidone, or clo-
zapine) about US inpatients with psychotic disorders, of 
whom 36 were diagnosed with BD (unspecified subtypes), 
documented equal rates of antipsychotic polypharmacy (two 
or more drugs), and antipsychotic monotherapy (n=18 or 50% 
each group). It also documented the association of short-term 
treatment with multiple antipsychotics to major increase 
in drug exposure, adverse events, and time in the hospital, 
with no apparent gain in clinical benefit.46 An updated 2008 
report by Centorrino et al still based on 2004 records of 
antipsychotic polypharmacy in US inpatients documented 
very high rates of polytherapy including one antipsychotic 
drug (80%) or two or more antipsychotics (23%) at once for 
at least 3 consecutive days in the BD subset of the sample 
wherein BD subjects formed (n=37 out of 305 or 12.13%). 
Yet again, no clear-cut stratification between FGA and SGA 
was documented for, across varying BD subsets.45 Concern-
ing the antipsychotic prescribing patterns in US outpatients, 
a chart review of 2003–2004 data using a permissive opera-
tive definition of two or more antipsychotics involving also 
BD cases (n=511, no stratification of results across differ-
ent BD subtypes) documented antipsychotic polypharmacy 
prevalence rates of 10% (53 cases), with accounted SGAs 
being risperidone, olanzapine, and quetiapine, although once 
again results were not stratified distinguishing between FGA 
vs SGA prescription trends.47
Polypharmacy in special BD populations
Little is known about the practice of polypharmacy among 
special population of BD, and virtually no data exist about 
any eventual difference in care based on ethnicity in non-US 
samples. Sometimes, rates have been documented in quali-
tative but not quantitative way, as it was the case of BD 
inpatients with SUD reported to receive both higher number 
and doses of both conventional mood stabilizers and SGAs 
compared to non-SUD lifetime comorbidity.69 Only a handful 
of studies have nonetheless provided essential quantitative 
data for alternative special settings/population of BD. Our 
knowledge is relatively limited even with respect to the 
practice of polypharmacy in BD inmates. Two longitudinal 
12-week studies by Kamath et al documented strikingly high 
prevalence rates for polypharmacy (use of three or more 
psychotropic medications at one) in 84% of the cases (out 
of a total sample of 40 BD-I or BD-II cases, equal ratios for 
males and females)43 urging the need for standard medication 
algorithms to reduce the polypharmacy in the correctional 
setting, with a special reference to antidepressant and antip-
sychotic drugs.70 Similarly, despite the acknowledgment 
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that pharmacological treatments for BD have historically 
been associated with neurocognitive side effects, espe-
cially in elderly subjects or otherwise possibly cognitively 
vulnerable subjects who would be particularly sensitive to 
polypharmacy,71,72 very little is known about these subjects, 
including bipolar subjects with intellectual disabilities (IDs). 
A report on 101 BD patients (F/M, n=59/41) aged 60 and 
older (mean age: 68.9±7.8 years), of whom 57 (56%) BD-I 
and 44 (44%) BD-II cases, with an onset of first affective 
symptoms before age 50 in 75.6% cases, was nonetheless 
studied with respect to polypharmacy (two or more psycho-
tropic medications), which was documented in 31.7% of the 
cases (n=32), with equal daily median number of psychotro-
pic medications in both BD-I and BD-II cases (median =2; 
interquartile range =3). Interestingly enough, among other 
classes of psychotropic drugs, lithium was the most fre-
quently prescribed one in BD-I and BD-II cases: 63.2% 
vs 43.1%, respectively.49 Regrettably, evidence about the 
practice of polypharmacy in BD outpatients with ID is even 
less conclusive, with the only available quantitative reports 
on the matter failing to provide any accurate stratification of 
results beyond the generic statement of similar polypharmacy 
rates occurring in ID (n=59) and non-ID (n=16) cases (range: 
24%–38%) based on the operative criterion of two or more 
drugs rates in the ID (n=59)50 or relying on unrepresentative 
subsets of BD cases,73 despite the widespread and contro-
versial clinical use of polypharmacy even for BD subjects 
with ID.74 Similarly, only one study about the practice of 
polypharmacy involving pregnant bipolar women could meet 
our inclusion criteria.32 Complete retrospective data ∼115 
pregnancies, 75 of whom were followed throughout gestation 
while 40 had data for one certain gestational period, based on 
the Medicaid database of 5,000 women coded according to 
the International Classification of Diseases, Ninth Revision 
within years 2002–2004 indicated that the mean number of 
medications taken during pregnancy for manic BD-I cases 
was three (range: 0–10; mode =3), whereas 26.8% of the 
pregnant women filled prescriptions for six to ten medica-
tions during their pregnancy. Surprisingly, no dose change 
was made for the prescribed medications to accommodate 
changing metabolism across pregnancy. The most frequently 
prescribed psychotropic medications were from the opiate 
family, most likely due to comorbid diagnoses (especially 
SUD). However, the effects of taking multiple medications on 
pregnancy outcome and fetal development were unknown.32 
These findings are nonetheless compelling, especially con-
sidering that according to the clinical records of 53 fertile 
women with different mental illnesses (including 24 BD 
cases), about one-third (n=8 or 36%) were taking more than 
one psychotropic medication within the first trimester of an 
unplanned pregnancy.75
Polypharmacy and treatment adherence 
in BD
The association between polypharmacy (two or more psy-
chotropic medications at once) and self-reported adherence 
with daily dose of mood stabilizer (lithium, valproate, lam-
otrigine, carbamazepine, or oxcarbazepine) was obtained by 
Bauer et al35 for 312 BD patients (BD-I, n=198; BD-II =100; 
and BD-NOS =14) over a 6-month period, accounting for 
the mean daily number of psychotropic drugs, which was 
3.1±1.6 (7.0±4.2 pills daily). No significant association was 
found between the daily number of medications and the 
daily number of pills, although the smaller the dosage of 
mood stabilizer taken, the higher the self-reported adherence 
to overall psychotropic prescriptions.35 In order to further 
characterize the factors associated with irregularity of daily 
dosage of antidepressants in BD, Bauer et al gathered self-
reported information about medication dosage and mood 
ratings from 144 BD patients (BD-I, n=67 or 47.2%; BD-II, 
n=65 or 45.8%; and BD-NOS, n=10 or 7%) who received 
treatment as usual (of whom, 111 were also taking a mood 
stabilizer).51 Regularity was measured using the “approxi-
mate entropy” (ApnEn), which is the tendency that values 
within a time series and remains the same on incremental 
comparisons.76 The authors documented that although the 
mean percentage of days with missing doses was only 18.6%, 
there was a wide range of regularity in the daily antidepres-
sant dosage. Drug holiday and polypharmacy (namely the use 
of two or more psychotropic drugs) were also significantly 
associated with irregularity (P=0.005), as it was the case for 
“pill burden” (P=0.005), and depression (P=0.015). Neither 
the percentage of days missing doses nor the drug holidays 
were associated with any demographic or clinical factors in 
the sample at study, which predominantly included female 
cases over male ones (F:M, n=108:36 or 75% vs 25%). 
Interestingly enough, the authors concluded that irregularity 
in daily dosage may be more dependent on the individual 
rather than on a specific drug, despite there being no assess-
ment of temperamental or personality traits of the involved 
patients over the 100-day follow-up period. Nonetheless, 
conclusive evidence about the association of treatment 
nonadherence and polypharmacy in BD remains elusive, as 
a 2008 report by Baldessarini et al indicated that prevalent 
lack of treatment at 1 year was associated with sustained 
mood-stabilizer adherence (subgroup, n=620), with those 
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patients on lithium or lamotrigine being more often adher-
ent than those prescribed with valproate, carbamazepine, or 
oxcarbazepine (nonadherent subgroup, n=1,577; uncertain 
cases were excluded in secondary analyses).
Polypharmacy rates and concordance with standard 
treatment guidelines in BD
Polypharmacy accounted for nonconcordance with varying 
different guidelines for the pharmacological management 
of BD as documented by a Korean chart review using the 
permissive operative criterion of two or more psychotropic 
medications at once.29 The study included 1,447 BD patients, 
including 990 BD-I cases (of whom, n=480 being currently 
manic inpatients; n=113 being depressive inpatients; and 
n=397 being outpatients) and 457 BD-II patients (of whom, 
n=190 being depressive inpatients and n=267 being outpa-
tients. The authors concluded that varying degree of concor-
dance rates across different guidelines essentially depended 
on the structure of heterogeneous guidelines themselves. 
For example, the 2009 edition of the Canadian Network for 
Mood and Anxiety Treatments (CANMAT)77 and 2010 of 
the Korean Algorithm for Bipolar Disorder (KMAP-BP) 
guidelines had identical initial strategy for mania. In the 
manic inpatient group, the initial treatment strategy for 317 
(66.0%) of 480 patients was equally concordant with both 
these latter guidelines. Nonconcordant initial treatment strate-
gies included SGA polypharmacy (22.1%), mood-stabilizer 
polytherapy (9.6%), and use of carbamazepine (1.9%) or typi-
cal antipsychotics (0.4%). Approximately half of concordant 
cases at the initial step had continued the same strategy for the 
entire treatment period (176 of 317, 55.5%). The concordance 
rate was lower for the next step in the treatment. The overall 
concordance rate with the CANMAT guidelines was 48.7% 
(234 of 480), and the concordance rate with the KMAP-BP 
guidelines was 43.8% (210 of 480). Mean duration to proceed 
to the next treatment step (adding or discontinuing medica-
tion) was ∼15 days. In addition, the CANMAT guidelines 
provide an algorithm among bipolar depression only for bipo-
lar I disorder (n=113). In the depressive inpatient group, only 
30 cases (26.5%) were concordant with the initial treatment 
strategy of the CANMAT guidelines. More than half of the 
subjects were treated with the combination treatment, which 
was not included in the first step of the CANMAT algorithm. 
The overall concordance rate with the CANMAT guidelines 
was only 18.6% (21 of 113). Most nonconcordant subjects 
started two or more different medications concomitantly. 
The concordant rate for bipolar depression with the initial 
strategy of the KMAP-BP guidelines was 63.4% (192 of 
303), as KMAP-BP included mood stabilizer plus SGA as 
one of the first options for bipolar depression. Nonconcordant 
initial treatment strategies essentially regarded SGA poly-
therapy and multiple mood stabilizers at once. The overall 
concordance rate with the KMAP-BP guidelines was 46.9% 
(142 of 303). When compared the concordance rate with 
the 2006 edition of the American Psychiatric Association 
(APA) practice guidelines78 and the 2009 edition of the World 
Federation Societies for Biological Psychiatry (WFSBP) 
guidelines,79 the overall concordance rates for mania were 
only 7.3% and 2.1%, respectively. The authors concluded 
that nonconcordance occurred mainly because lithium is not 
recommended as the first line because of its potentially slower 
onset of action, and monotherapy should always proceed in 
the WFSBP guidelines. Finally, concerning the treatment 
of acute depression, the concordance rate with the APA or 
WFSBP guidelines was much lower, that is, 5.6% with the 
APA guidelines and 11.9% with the WFSBP guidelines. This 
latter quantitative evidence is in line with Western reports, 
pointing out a major impact of polypharmacy in determin-
ing poor adherence toward standard prescription guidelines, 
especially in the case of antipsychotic polypharmacy in the 
inpatient and/or the inmate units.36
Discussion
Study limitations and implications and 
premises
Most of the limitations of the present systematic review are 
intrinsically related to the potential biases hampering the 
validity of the included studies and should be taken into 
account in the interpretations of the overall results presented 
herein. For example, given that medication decisions may be 
especially driven by mood episode polarity (eg, antidepres-
sants prescribed for a depressive vs a manic episode), the fact 
that a number of included studies did not punctually stratify 
their own results using mood episode polarity as covariate 
in any multivariate analysis of significant univariate effect 
(if ever carried) should be considered. The inconsistency of 
the operative definitions of polypharmacy invariably affects 
the generalizability of the quantitative and qualitative results 
too, even if we strived to stratify our own results accordingly. 
Specifically, the ORs and risk ratios of the given studies 
included in the present review may differ across different 
studied samples according to the operative definitions of 
polypharmacy, sex, history of suicide attempt, associated 
medical and/or psychiatric clinical correlates, and Cohen’s d 
effect sizes could be documented or extracted whenever pos-
sible only. Publication and measurement (namely “diagnostic 
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shift”) biases should also be regarded. Indeed, most of the 
recently introduced SGA or novel antidepressant drugs 
could not be assessed by previous studies. In addition, little 
is known about specific regional or cultural settings despite 
the potential impact of either cultural or pharmacoeconomic 
issues on prescription trends across different high resource 
regions,80,81 although strikingly high prevalence rates of 
polypharmacy were documented even in nonhigh resource 
settings worldwide, especially when permissive operative 
criteria were adopted.28,31,82 With respect to low-income and/
or non-Western regions, even when such information was 
available, it often came from outdated or generic reports. 
For example, low rates of “affective psychosis” in contrast 
to “schizophrenia” cases were documented in Nigeria based 
on pharmacological treatment records dating back to the 
late 1970s.83 Yet, much higher prevalence rates of “affective 
disorders” was documented in the same region by a more 
recent multidiagnostic study focusing on polypharmacy.84 
In this regard, we speculate that a diagnostic shift from 
schizophrenia to “affective disorders”, in the broader sense, 
thus encompassing BD too, may reflect either differential 
settings (in- vs outpatient facilities) or the diagnostic revi-
sions occurred within the past decades.81,85,86 These are 
additional crucial issues in the interpretation of cumulative 
evidence on polypharmacy “in BD” obtained from studies 
published within a large time frame beyond the sole “regional 
setting” variable. Finally, it is worth mentioning that while 
the stringent selection criteria adopted through this qualita-
tive and quantitative review greatly reduced the number of 
contributes considered of adequate quality, this systematic 
selection ideally emphasized just the most rigorous and 
clinically relevant results on the topic, which is also a critical 
issue for the topic at issue considering the discrepancy exit-
ing between real-world practice and the standard treatment 
guidelines on the matter.
Final remarks and implications for the 
clinical practice
[…] Doctors are men who prescribe medicines of which 
they know little, to cure diseases of which they know less, 
in human beings of whom they know nothing.
This much pessimistic quote was attributed to François-
Marie Arouet (1694–1778), best known by his nom de 
plume Voltaire. It was corroborated by the position of his 
countryman Philippe Pinel (1745–1826), who “was one 
of those physicians who reacted most strongly against 
the abuses of polypharmacy [multiple medications]” as René 
Semelaigne wrote in 1888, a later-born psychiatrist whose 
family had memories of Pinel.87 This still reflects the attitude 
of many of modern prescribers toward BD polypharmacy.
Indeed, since 19th century, the practice of polyphar-
macy for what it is nowadays considered BD has spread 
consistently worldwide. It has been documented a tenfold 
increase in percentage of patients receiving three or more 
psychotropic medications at discharge between 1974 and 
1995,88 with much higher rates virtually occurring within 
the past 2 decades due to the increasing availability of novel 
pharmacological compounds, including antidepressant and 
SGA drugs, in the absence of any novel “silver bullet” drug 
for BD after the introduction of lithium.7,89,90
While a firm position either in support or against the 
practice of polypharmacy in BD is out of the scope (and 
the possibility) of the present evidence-based qualitative 
and quantitative synthesis, it is nonetheless worth not-
ing that polypharmacy for BD is an extremely common 
scenario, often poorly, scientifically sound. Not all of the 
polypharmacy routine follow a pharmacological and/or 
diagnostic rationale or the standard guidelines, with the 
ultimate risk of further burden on the patents rather than 
additional benefit. Thus, it is mandatory that future rep-
lication studies will expand the current knowledge about 
the prevalence and the clinical features of polypharmacy 
testing the reliability and validity of different operative 
definitions, ideally focusing on selective clinically sound 
potential moderators currently precluding any reliable 
quantitative extraction on the matter beyond the qualita-
tive synthesis provided by a systematic review, with a 
special emphasis toward affective temperaments, history 
of suicidal behavior, and/or rapid cycling and mixed 
features, especially considering that the ultimate goal in 
the management of BD should be paving the ground for 
long-term stability (thus regarding efficacy, tolerability, 
sustainability, and adherence issues) rather than merely 
focusing on the acute phase management.
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